Dynamic Estimation of Cardiac Output in the Operating Room
NCT ID: NCT04926220
Last Updated: 2021-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
92 participants
OBSERVATIONAL
2021-09-15
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main goal of this study is to compare the relative changes in cardiac output obtained during hemodynamic interventions (fluid challenge or vasopressors) using PRAM and LTIA versus esophageal doppler. Parameters measured for the primary objective: 1. Continuous measurement and recording of the invasive blood pressure signal 2. Continuous and simultaneous measurement of cardiac output by MostCareUp (Vytech, Padova, Italy) and esophageal doppler. 3. Estimation of cardiac output from the arterial pressure signal by means of a digital analog converter using the LTIA algorithm connected to the patient's scope. For all patients, data from the cardiac output monitors are recorded throughout the procedure and the resuscitation stay. The secondary objective is to study the hemodynamic parameters of ventriculoarterial coupling calculated by the PRAM method and measured by esophageal doppler, other than CO and SV during therapeutic challenges. Parameters measured for the secondary objective: Global Afterload Angle (GALA), the value of the dicrote wave, dP/dtmax (myocardial contractility index), cardiac efficiency (CCE), arterial elastance, the total impedance of the system (Ztot).
Experimental design: this is a single-center, observational prospective study The study concerns adult patients benefiting from intraoperative hemodynamic optimization under general anesthesia, including routine monitoring of blood pressure and measurement of cardiac output by esophageal Doppler.
This study is "non-interventional" on adult patients undergoing interventional radiology, surgery under general anesthesia, or admitted to the ICU for postoperative organ failure. All measurements are obtained from standard monitoring including blood pressure and cardiac output measurement by transesophageal Doppler. Monitoring includes continuous electrocardiogram, SpO2, ventilatory parameters and depth of anesthesia by Bispectral Index. During the anaesthesia consultation, the patients will be given a letter of information on the objectives and the course of the study. Their non-opposition to participating in this study will be collected at the latest during the pre-anesthetic visit, the day before the operation. The protocol starts on the day of the operation. For all patients, the procedures will be performed under general anesthesia with an intravenous anesthesia protocol with a concentration objective (Orchestra® Base Primea - Fresenius Kabi France). The protocol does not interact with the care procedure. On the day of the procedure, the MostCareUp (Vytech, Padova, Italy) will be connected in series with the pressure head already in place. The blood pressure signals will be continuously recorded to allow estimation of the cardiac output by the LTIA method using an analog-to-digital converter. This calculation is made from the signal that has been transmitted to the multiparametric scope monitor and is therefore not directly connected to the patient. The acquisition of the analog signal is done via USB2.0 thanks to a Video Capture Card equipped with a converter. The software recalculates with its algorithm an estimation of the cardiac output from the data. The clinician in charge in the operating room will use only the hemodynamic data from the esophageal Doppler to guide his therapeutic strategy. Synchronization of the 2 devices. Recording of events during therapeutic tests if there is an indication for treatment. Usual protocol of the therapeutic challenges service: Patient receiving intraoperative vascular filling titration to optimize cardiac output (maximize SV/CO), patient with persistent arterial hypotension (MAP \< 65 mmHg or \< 80% of baseline) during the procedure despite adequate depth of anesthesia (BIS 40-50) and optimized cardiac output motivating vasopressor injection. For all patients, data from the 2 cardiac output monitors and hemodynamics will be collected during and after the therapeutic tests. Under no circumstances will a decision on therapeutic strategy be made based on PRAM or LTIA data. No additional complementary examination will be performed. The physician in charge of the study collecting the data does not intervene at any time in the management of the patient. The implementation of this type of intraoperative monitoring does not prolong the duration of anesthesia.
The measure of agreement the investigators will use is the intra-class correlation coefficient. To compare 3 measurement modalities, assuming that the intraclass correlation coefficient for the measurement of VES variations will be 0.85 with a confidence interval with width of 0.1 and a first-species risk of 0.05, 84 patients must be included. It is expected that the signals of 10% of the included patients will be of insufficient quality for their exploitation. Therefore, the calculated sample size is 92 patients.
Results will be expressed as mean (standard deviation) or median (interquartile range) depending on the normality of the data distribution. A Bland-Altman analysis for repeated measures will be used to evaluate the agreement between the cardiac output measured by esophageal Doppler and the cardiac output estimated by the two pulse wave monitors. It will be associated with a calculation of the bias and its 95% confidence interval, the upper/lower limits of agreement and their 95% confidence intervals, and the percentage error. A percentage of error less than or equal to 30% indicates the agreement of the technique with the reference method. The agreement of cardiac output variations measured by esophageal Doppler and pulse wave analysis will be evaluated by a Bland-Altman analysis. The percentage of agreement will be evaluated using a four-quadrant plot. Acceptable agreement is defined as greater than 90%. The analyses will be repeated in the filler and vasopressor subgroups. The ability of pulse wave monitors to detect responders to filling will be assessed and compared with esophageal doppler. Subjects will be defined as responders to volume expansion when the filling test increases the ESV by more than 10%.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients undergoing general anesthesia and benefiting from intraoperative hemodynamic optimization
Patients undergoing general anesthesia and benefiting from intraoperative hemodynamic optimization, including routine monitoring of blood pressure and measurement of cardiac output by trans-esophageal Doppler.
Trans-esophageal Doppler monitoring
Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
MostCareUP Haemodynamic Monitor
MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
Argos Cardiac Output (CO) Monitor
Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trans-esophageal Doppler monitoring
Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
MostCareUP Haemodynamic Monitor
MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
Argos Cardiac Output (CO) Monitor
Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eligible for an interventional radiology procedure or surgery under general anesthesia
* Monitoring of invasive blood pressure and cardiac output by trans-esophageal Doppler.
* Patients informed and having expressed their non-opposition to participation in this research
Exclusion Criteria
* Atrial fibrillation
* Contraindication to trans-esophageal doppler
* Patient opposed to protocol participation
* Pregnant woman
* Patient under judicial protection
* Patient without affiliation to a social security scheme
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
INSERM UMR-942, Paris, France
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alex HONG, MD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Joaquim MATEO, MD
Role: STUDY_DIRECTOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AP-HP, Lariboisière Hospital, Department of Anesthesiology and Intensive Care
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A00088-33
Identifier Type: OTHER
Identifier Source: secondary_id
APHP210311
Identifier Type: -
Identifier Source: org_study_id